Welcome to the new academic journal OBM Hepatology and Gastroenterology. Recent progress in understanding liver, biliary, pancreatic and gastro-intestinal diseases and their treatments has been observed in the world. OBM Hepatology and Gastroenterology publishes interesting and informative reviews, original articles, and invaluable case reports in this area. We also publish basic research as well as clinical research.

Hepatitis A virus (HAV), HBV, HCV, HDV, and HEV are still a serious issue worldwide. Treatments on these viruses have recently improved. However, liver fibrosis, cirrhosis and hepatocellular carcinoma are still critical conditions. We focus on all of these liver diseases. We also focus on broad-spectrum of gastro-intestinal diseases in this journal.

Please accept our special thanks for choosing to publish in the OBM Hepatology and Gastroenterology. We are looking forward to your submissions for OBM Hepatology and Gastroenterology.

Archiving: full-text archived in CLOCKSS.

Rapid publication: manuscripts are undertaken in 6.8 days from acceptance to publication (median values for papers published in this journal in 2020, 1-2 days of FREE language polishing time is also included in this period).

Free Publication in 2021
Current Issue: 2021  Archive: 2020 2019 2018 2017

Special Issue

New and Old Therapeutic Options for Crohn’s Disease

Submission Deadline: May 01, 2019 (Open) Submit Now

Guest Editor

Tony C. K. Tham, MD, MB BCh BAO, MSc, FRCP, FRCPI

Consultant Gastroenterologist and President -elect, Irish Society of Gastroenterology
Division of Gastroenterology, Ulster Hospital, Dundonald, Belfast, United Kingdom

Website | E-Mail

Research Interests: Gastrointestinal haemorrhage; inflammatory bowel disease; endoscopic mucosal resection; pancreatobiliary disease; ERCP; dysplastic Barretts; gastrointestinal consequences of pelvic radiotherapy

About This Topic

There are currently four biologic therapies available for Crohn’s disease and many new therapeutic options such as small molecules in the development pipeline. There are also currently other well established drugs such as thiopurines, methotrexate, budesonide and steroids for the treatment of Crohn’s. In addition, other therapeutic options include surgery, endoscopic therapy and dietary intervention. This special issue seeks submissions that address the role of these treatment options for the management of Crohn’s, how these options can be used in treatment pathways, how these therapies can be combined to best effect, and how to select the right patient for the right intervention. The submissions can be in the form of review articles, opinions or original research. We would like to invite you to submit your work for consideration of publication in this special issue.

Planned Papers

Title: Managing Fatty Liver Disease in the Inflammatory Bowel Disease Patient
Authors: Ordway S, Sadowski B, Tritsch A, Singla M
Affiliations: Uniformed Services University of Health Sciences, Bethesda, MD; Walter Reed National Military Medical Center, Bethesda, MD

Title: The management of perianal fistulas in Crohn's diaseas: systematic review
Authors: Roberta Tutino, Claudia Carolla, Saverio Barbera, Gianfranco Cocorullo, Gaspare Gulotta
Affiliations: Department of Surgical, Oncological and Stomatological Disciplines, University of Palermo, Palermo, Italy

Title: Advanced endoscopic therapies in Crohn's disease
Authors: Wong A, Lee SD
Affiliation: Department of Medicine, Division of Gastroenterology, University of Washington Medical Center, Seattle, WA, USA.
Abstract
Crohn’s disease is a chronic progressive transmural disease that overtime leads to complications such as strictures, fistulas, and abscesses. While the majority of patients present with non-penetrating disease at diagnosis, around 50-60% develop fibrostenotic disease over time. Endoscopy serves an important role in the diagnosis, management, and treatment of inflammatory bowel disease. It not only helps distinguish between Crohn’s disease and ulcerative colitis, but can also diagnose and manage mechanical adverse events. Endoscopic therapy, a less invasive alternative to surgical options, bridges the gap between medical and surgical treatments. Endoscopic tools include video capsule endoscopy, small bowel enteroscopy, endoscopic balloon dilation, as well as other more novel investigational therapies. This review will focus on using advanced endoscopic therapeutic techniques for the diagnosis and management of complications in Crohn’s disease.

Title: New and Old Therapeutic Options for Luminal Crohn's Disease - An Overview of Current Literature
Authors: Rachel Rutherford, Patrick B Allen
Affiliation: Department of Medicine and Gastroenterology, SE Trust, Belfast NI UK
Abstract
Crohn's Disease (CD) is a chronic inflammatory, relapsing and remitting condition that leads to structural damage of the bowel wall. It can be located in any part of the gastrointestinal tract with associated extra-intestinal manifestations. It varies in severity having many complications resulting in significant morbidity. In the past decade medical management of CD has evolved rapidly and with ongoing research it continues to show promising novel therapies. In this article we aim to give an overview of current literature on old and new therapy options for luminal CD looking at data including their efficacy and safety. With new oral biologic therapies such as the Janus Kinase inhibitor and gut specific targeted therapies developing their place in this ever growing marketplace treatment options for physicians are going to become even more challenging.

Publication

Open Access Perspective

Missing the Target to Treat in Crohn’s Disease

Received: 05 April 2019;  Published: 30 September 2019;  doi: 10.21926/obm.hg.1903036
Open Access Review

Advanced Endoscopic Techniques in the Evaluation and Treatment of Fibrostenotic Crohn's Disease

Received: 09 May 2019;  Published: 16 August 2019;  doi: 10.21926/obm.hg.1903033

Abstract

Crohn’s disease is characterized by chronic intestinal inflammation that can result in significant morbidity and loss of intestinal function over time. Many novel treatments for Crohn’s disease are being developed, but a significant portion of patients still requires surgical therapy for structuring [...]
Open Access Review

Conventional and Future Therapies for Crohn's Disease

Received: 20 May 2019;  Published: 14 August 2019;  doi: 10.21926/obm.hg.1903032

Abstract

Crohn's disease is part of a group of diseases termed inflammatory bowel disease. Guidelines have long advocated the use of steroids for acute flare up and Current goals of treatment include enhancing long-lasting remission, preventing relapse, reducing the need for surgery, preventing complications [...]
Open Access Review

New and Old Therapeutic Options for Luminal Crohn's Disease - An Overview of Current Literature

Received: 25 February 2019;  Published: 12 August 2019;  doi: 10.21926/obm.hg.1903031

Abstract

Crohn's Disease (CD) is a chronic inflammatory, relapsing and remitting condition that leads to structural damage of the bowel wall. It can be located in any part of the gastrointestinal tract with associated extra-intestinal manifestations. It varies in severity having many complications resulting [...]
Open Access Opinion

The Curing of Crohn’s Disease

Received: 06 January 2019;  Published: 04 June 2019;  doi: 10.21926/obm.hg.1902021

Abstract

Using the therapeutic intervention points identified by the Hruska Postulate, the probability of curing Crohn’s disease through destroying the anti-MAP template is discussed.
Open Access Review

Endoscopic Management of Crohn’s Disease Strictures

Received: 28 January 2019;  Published: 26 March 2019;  doi: 10.21926/obm.hg.1901015

Abstract

Crohn’s disease is a chronic inflammatory condition of the gastrointestinal tract which can result in luminal stenosis and up to 90% of patients requiring surgery during their lifetime. Medical management aims to reduce the inflammatory burden to prevent the development of inflammatory strictures, p [...]
Announcement
Newsletter

TOP